Clinical Outcomes and Institutional Experience of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer.

ABSTRACT:

Purpose

Prompted by COVID-19 and publication of the FAST-Forward study, our institution rapidly implemented ultrahypofractionated radiation therapy (U-HFRT) for patients with early-stage breast cancer. Our objective was to evaluate our early experience and toxicity outcomes for U-HFRT.

Methods and materials

Patients with consecutive stage 0-II breast cancer treated with adjuvant whole breast radiation therapy (RT) were evaluated. Patient demographics and treatment characteristics were extracted and categorized into 2 cohorts: U-HFRT, 26 Gy/5 fractions (F) and M (moderate)-HFRT, 40.05 Gy/15F. Physician-assessed skin toxicity was evaluated using the Radiation Therapy Oncology Group radiation morbidity scale at baseline/during RT, 1 to 90 days post-RT and >90 days post-RT. Desc

SUBMITTER: Othman H 

PROVIDER: S-EPMC12800407 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature